Panitumumab treatment cycles

Panitumumab is approved in the United States for the treatment of patients with EGFR-positive metastatic colorectal cancer who have disease progression during or after receiving chemotherapy containing fluoropyrimidine, oxaliplatin, and irinotecan. Panitumumab is a fully human monoclonal antibody that targets the extracellular domain of EGFR. Immunohistochemical expression of EGFR was evaluated in all trials in which patients with low and negative EGFR metastatic colorectal cancer responded to treatment.

Panitumumab comes as a solution (liquid) by infusion (injection into a vein), usually by a doctor or infusion doctor or nurse, usually every 2 weeks (14 days). If you develop a reaction while receiving panitumumab, you may receive a lower dose in the future, or you may not be able to receive panitumumab, your doctor will make a decision based on the severity of the reaction. Panitumumab may cause serious or life-threatening reactions while receiving medication. If any of the following symptoms occur during treatment, such as difficulty breathing or swallowing, shortness of breath, chest tightness, itching, etc., or if a severe reaction is experienced, your doctor will stop the medication and treat the symptoms of the reaction.

It is understood that the original version of panitumumab has not yet been launched in China, and therefore it has not been covered by medical insurance. The price of the Hong Kong original version of panitumumab sold in Hong Kong, China100mg/5mL may be around RMB 9,000 (the price may fluctuate due to exchange rates). There are currently no generic drugs of Panitumumab on the market. If a patient has a need to purchase Panitumumab, please consult a medical consultant for specific prices and more drug information.